サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1176602

予防ワクチンの世界市場-2023-2030

Global Preventive Vaccine Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
予防ワクチンの世界市場-2023-2030
出版日: 2022年12月26日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

予防ワクチンの市場規模は、予測期間（2023～2030年）においてCAGR5.3％で成長するとされています。

予防ワクチンとは、特定の病原体に対する免疫力を刺激する生物学的製剤の一種です。ワクチンは一般的に、病気を引き起こす微生物に類似した物質を含み、通常、その微生物や毒素の死骸または弱毒化したものから作られます。

市場力学

予防ワクチンの世界市場を牽引する主な要因は、世界の疾病数の増加、研究開発費の増加、予防ワクチンに関する国民の意識です。新規製品上市の増加は、予防ワクチン市場の成長に寄与しています。

研究開発への投資の増加と新規製品の上市の増加は、市場の成長を促進すると予想されます。

麻疹、ジフテリア、ポリオ、風疹、インフルエンザなど、さまざまな疾患の予防や治療にこれらの予防ワクチン製品が採用されるようになり、新規製品の上市が増加していることが予防ワクチン市場の原動力となっています。また、世界の疾病の増加も市場の成長を後押ししています。多くのヘルスケア企業が新製品を開発するために研究開発活動を活発化させています。

予防ワクチンは、子どもや大人における病気の予防や蔓延の防止に使用されます。さまざまな疾病の増加により、これらのワクチンの市場は世界的に拡大しています。さらに、新規ワクチンの研究開発の増加や、主なプレイヤーによる技術的に高度な製品の提供も、市場の成長に重要な役割を果たすと考えられています。

様々な新規製品の上市、規制当局の承認、調査研究は、市場の成長に寄与しています。例えば、2022年4月11日、田辺三菱製薬株式会社は、BIKEN（大阪大学微生物病研究会）が共同開発したジフテリア、百日咳予防、破傷風、ヘモフィルス・インフルエンザ菌b型（Hib）、急性骨髄炎（ポリオ）に関する混合ワクチンの販売承認を厚生労働省に申請したと発表しています。全国予防接種計画」によると、2014年に指定された開発優先度の高いワクチンとして、この5疾病に活用される混合ワクチンが選ばれています。

予防ワクチンの副作用は、市場の成長を阻害すると予想されます。

しかし、様々な種類のワクチンに関連する様々な軽微な副作用は、市場の成長を阻害する可能性があります。DTaPワクチン接種後は、発熱、注射した場所の腫れや痛み、騒がしさ、疲れやすさ、嘔吐、食欲不振などが起こることがあります。インフルエンザワクチン接種後は、接種した部分が赤く腫れたり、筋肉痛や頭痛、発熱などが起こることがあります。

インフルエンザワクチン接種後、鼻づまり、鼻水、頭痛、喘鳴が起こることがあります。MMR接種後に、頬や首の腫れ、関節のこわばりや一時的な痛み（主に成人や10代の女性）が起こることがあります。ロタウイルスワクチン接種後に、イライラしたり、嘔吐したり、一時的に軽い下痢をすることがあります。

COVID-19の影響分析

パンデミックは、世界の金融への期待、オペレーション、危機対応戦略にプラスの影響を与えています。COVID-19の発生は、ヘルスケア産業に深刻な影響を与えました。予防ワクチン市場は、COVIDワクチンの様々な研究と臨床試験が本格的に開始されたため、COVIDによって巨額の利益を経験しました。COVIDとその亜種の世界の蔓延を防止するためのワクチンが急務となっています。様々な取り組み、製品の発売、技術革新、コラボレーション、合併が世界中で起こっており、市場の成長を後押ししています。例えば、2022年11月10日、サノフィとGSKは、共同開発した次世代COVID-19ブースターワクチン「VidPrevtyn Beta」が、18歳以上の成人におけるCOVID-19予防のために欧州委員会から承認されたと発表しています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 研究開発投資の増加
      • 新製品上市の急増
      • 疾病の発生率の増加
    • 抑制要因
      • ワクチン別副作用
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 ワクチンの種類別

  • 弱毒性ワクチン
  • 不活性化ワクチン
  • サブユニット、リコンビナント、コンジュゲート、多糖類ワクチン
  • mRNAワクチン
  • トキソイドワクチン
  • ウイルスベクターワクチン

第8章 投与経路別

  • 経口
  • 皮下投与
  • その他

第9章 疾患別適応症

  • 肺炎球菌疾患
  • 水痘（みずぼうそう）
  • ヒト乳頭腫ウイルス
  • インフルエンザ
  • 髄膜炎菌感染症
  • MMR（はしか、おたふくかぜ、風疹）
  • ポリオ
  • 肝炎
  • デング熱
  • DPT（ジフテリア、百日咳、破傷風）
  • ロタウイルス
  • 黄熱病
  • 腸チフス
  • その他

第10章 エンドユーザー別

  • 成人
  • 小児科

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • AstraZeneca
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Astellas Pharma, Inc.
  • Pfizer, Inc
  • Johnson & Johnson
  • GSK plc
  • Merck & Co., Inc.
  • Sanofi
  • Bavarian Nordic
  • Emergent Biosolutions
  • Mitsubishi Tanabe Pharma Corporation

第14章 予防ワクチンの世界市場-DataM

目次
Product Code: DMBT43

Market Overview

Preventive Vaccine Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 5.3% during the forecast period (2023-2030).

A preventive vaccine is a kind of biological preparation which stimulates immunity to a specific pathogen. A vaccine commonly contains an agent similar to the disease-causing microbe and is usually made from killed or weakened forms of the microorganism or its toxins.

Market Dynamics

The major factors driving the global preventive vaccine market are an increase in the number of diseases globally, rising research and development expenditure and awareness among the population regarding these preventive vaccines. An increase in novel product launches contributes to the growth of the preventive vaccine market.

The increasing investment in R&D and rising novel product launches are expected to drive the market's growth.

The rising adoption of these preventive vaccine products for the prevention or treatment of various diseases, such as measles, diphtheria, polio, rubella, influenza and many more and the rising number of novel product launches drive the preventive vaccine market. An increase in diseases globally is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

The preventive vaccine is used for the prevention of diseases and the spreading of these diseases in children and adults. The market for these vaccines is increasing worldwide due to the increasing number of different diseases. Moreover, the increase in research and development of novel vaccines and the availability of technologically advanced products by key players are also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals and research studies contribute to the market's growth. For instance, in April 11, 2022, Mitsubishi Tanabe Pharma Corporation announced that BIKEN (The Research Foundation for Microbial Diseases of Osaka University) submitted the application to the Ministry of Health, Labour and Welfare for their jointly developed combination vaccine marketing authorization for diphtheria, prophylaxis of pertussis, tetanus, Haemophilus influenzae type b (Hib) and acute poliomyelitis (polio). According to the "National Immunization Plan," this combination vaccine utilized for five diseases has been chosen as the vaccine with high development priority specified in 2014.

The side effects associated with preventive vaccines are expected to hamper the market's growth.

However, various minor side effects associated with different types of vaccines may hinder the market's growth. Fever, swelling or soreness where the shot was given, fussiness, tiredness, vomiting and loss of appetite can occur after DTaP vaccination. Redness or swelling happens where the shot is given, and muscle aches, headaches and fever can happen after influenza vaccination.

After influenza vaccination, nasal congestion, runny nose, headache and wheezing can happen. In the cheeks or neck, swelling of the glands or stiffness and temporary pain in the joints (mostly in adults or teenage women) sometimes happen after MMR vaccination. Irritability, vomiting, or temporary, mild diarrhea, can occur after the rotavirus vaccine.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The preventive vaccine market has experienced huge profits due to COVID, as various research and clinical trials got started in full swing for COVID vaccine. An urgent need for vaccines to prevent the spreading of COVID and its variant across the globe. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in November 10, 2022, Sanofi and GSK announced the approval of their jointly developed VidPrevtyn Beta, the next-generation COVID-19 booster vaccine, by the European Commission for COVID-19 prevention in adults aged 18 years and older.

Segment Analysis

The live-attenuated vaccines segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The live-attenuated vaccines segment is the highest market holder in the global preventive vaccine market. The global preventive vaccine market is segmented based on vaccine type: live-attenuated vaccines, inactivated vaccines, subunit, recombinant, conjugate, and polysaccharide vaccines, mRNA vaccines, toxoid vaccines and viral vector vaccines. The live-attenuated vaccines segment is the largest market shareholder due to its better efficacy and results, increasing diseases and rising adoption of these preventive vaccines.

The live-attenuated vaccines utilize an attenuated or weakened form of the microbe that causes a disease. As these vaccines are like the natural infection they help avert, they provide a long-lasting and strong immune response. Most of the live vaccines, in just 1 or 2 doses, can provide a lifetime of protection contrary to the microbe and the disease caused by it. These vaccines are used for the protection against smallpox, rotavirus, yellow fever, chickenpox and combined vaccine of measles, mumps, and rubella (MMR).

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in February 24, 2022, Mitsubishi Tanabe Pharma Corporation announced that GlaxoSmithKline plc and Medicago Inc., its affiliated company, jointly announced receiving full approval for COVIFENZ (COVID-19 vaccine) from Health Canada. COVIFENZ is a virus-like particle vaccine that is administered with the pandemic adjuvant of GSK indicated for COVID-19 prevention.

Geographical Analysis

North America holds the largest market share in the global preventive vaccine market.

North America dominates the global preventive vaccine market, primarily due to its large population, excellent medical infrastructure, and rising number of diseases. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of types of vaccines for prevention of different disease indications such as pneumococcal disease, varicella, human papillomavirus, influenza, meningococcal disease, MMR (measles, mumps, rubella), polio, hepatitis, dengue, DPT (diphtheria, pertussis, and tetanus), rotavirus, yellow fever, typhoid fever and more, increase in pharmaceutical establishment across the region and government approvals and the presence of key players in the region are contributing to the growth of the preventive vaccine market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in October 10, 2022, GSK plc announced approval for its BOOSTRIX (Reduced Diphtheria Toxoid, Tetanus Toxoid and Acellular Pertussis Vaccine) by the US Food and Drug Administration (FDA) for immunization during the pregnancy to prevent pertussis (whooping cough) in infants.

Competitive Landscape

The preventive vaccine market is moderately competitive with local and global companies' presence. AstraZeneca, Astellas Pharma Inc., Pfizer, Inc, Johnson & Johnson, GSK plc, Merck & Co., Inc., Sanofi, Bavarian Nordic, Emergent Biosolutions, Mitsubishi Tanabe Pharma Corporation and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in August 16, 2022, GSK plc announced its completion of the acquisition of Affinivax Inc, a Cambridge-based clinical-stage biopharmaceutical company. Affinivax has initiated a novel class of vaccine development. The most advanced of them are next-generation pneumococcal vaccines.

GSK PLC.

Overview: GlaxoSmith Kline is a company that develops and provides vaccines, medicines and several consumer healthcare-related products. Its products impact the health of humans on a large scale.

Product Portfolio:

VidPrevtyn Beta: It is the next-generation COVID-19 booster vaccine developed for COVID-19 prevention in adults aged 18 years and older and approved by the European Commission.

Key Developments: In February 3, 2021, GlaxoSmithKline plc and CureVac N.V. announced a novel collaboration of €150M for the joint development of next-generation mRNA vaccines for preventing COVID-19 virus with the capability for a multi-valent approach to deal with multiple emerging variants with one vaccine.

The global preventive vaccine market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in investment in research and development
      • 4.1.1.2. Surge in novel product launches
      • 4.1.1.3. Increasing incidence of diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with vaccines
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Vaccine Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 7.1.2. Market Attractiveness Index, By Vaccine Type
  • 7.2. Live-attenuated vaccines*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Inactivated vaccines
  • 7.4. Subunit, recombinant, conjugate, and polysaccharide vaccines
  • 7.5. mRNA vaccines
  • 7.6. Toxoid vaccines
  • 7.7. Viral vector vaccines

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Subcutaneous
  • 8.4. Other

9. By Disease Indication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 9.1.2. Market Attractiveness Index, By Disease Indication
  • 9.2. Pneumococcal Disease *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Varicella
  • 9.4. Human Papilloma Virus
  • 9.5. Influenza
  • 9.6. Meningococcal Disease
  • 9.7. MMR (Measles, Mumps, Rubella)
  • 9.8. Polio
  • 9.9. Hepatitis
  • 9.10. Dengue
  • 9.11. DPT (diphtheria, pertussis, and tetanus)
  • 9.12. Rotavirus
  • 9.13. Yellow Fever
  • 9.14. Typhoid Fever
  • 9.15. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Adults *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Pediatrics

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. AstraZeneca *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Astellas Pharma, Inc.
  • 13.3. Pfizer, Inc
  • 13.4. Johnson & Johnson
  • 13.5. GSK plc
  • 13.6. Merck & Co., Inc.
  • 13.7. Sanofi
  • 13.8. Bavarian Nordic
  • 13.9. Emergent Biosolutions
  • 13.10. Mitsubishi Tanabe Pharma Corporation

LIST NOT EXHAUSTIVE

14. Global Preventive Vaccine Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and End-User
  • 14.3. Contact Us